Networks of blood proteins in the neuroimmunology of schizophrenia. by Jeffries, C.D. et al.
Jeffries et al. Translational Psychiatry  (2018) 8:112 
DOI 10.1038/s41398-018-0158-y Translational Psychiatry
ART ICLE Open Ac ce s s
Networks of blood proteins in the
neuroimmunology of schizophrenia
Clark D. Jeffries 1, Diana O. Perkins2, Margot Fournier3, Kim Q. Do 3, Michel Cuenod3, Ines Khadimallah3,
Enrico Domenici 4, Jean Addington5, Carrie E. Bearden6, Kristin S. Cadenhead7, Tyrone D. Cannon8,
Barbara A. Cornblatt9, Daniel H. Mathalon10, Thomas H. McGlashan8, Larry J. Seidman11, Ming Tsuang12,
Elaine F. Walker13 and Scott W. Woods8
Abstract
Levels of certain circulating cytokines and related immune system molecules are consistently altered in schizophrenia
and related disorders. In addition to absolute analyte levels, we sought analytes in correlation networks that could be
prognostic. We analyzed baseline blood plasma samples with a Luminex platform from 72 subjects meeting criteria for
a psychosis clinical high-risk syndrome; 32 subjects converted to a diagnosis of psychotic disorder within two years
while 40 other subjects did not. Another comparison group included 35 unaffected subjects. Assays of 141 analytes
passed early quality control. We then used an unweighted co-expression network analysis to identify highly correlated
modules in each group. Overall, there was a striking loss of network complexity going from unaffected subjects to
nonconverters and thence to converters (applying standard, graph-theoretic metrics). Graph differences were largely
driven by proteins regulating tissue remodeling (e.g. blood-brain barrier). In more detail, certain sets of antithetical
proteins were highly correlated in unaffected subjects (e.g. SERPINE1 vs MMP9), as expected in homeostasis. However,
for particular protein pairs this trend was reversed in converters (e.g. SERPINE1 vs TIMP1, being synthetical inhibitors of
remodeling of extracellular matrix and vasculature). Thus, some correlation signals strongly predict impending
conversion to a psychotic disorder and directly suggest pharmaceutical targets.
Introduction
Circulating levels of immune system proteins and rela-
ted signaling agents are consistently altered in schizo-
phrenia. This observation includes unmedicated ﬁrst
episode psychosis patients1,2 and persons at clinical high-
risk who subsequently convert to psychosis3–5. Consistent
ﬁndings include proteins in the immune system acute
phase response and in the plasminogen activating sys-
tem1. Many of the proteins inﬂuence brain function
directly, crossing blood–brain barrier (BBB) and signaling
glia or other perivascular cells. These immune signaling
molecules also regulate brain function by inﬂuencing BBB
endothelial cell function and general integrity. Such
ﬁndings support the hypothesis that psychosis involves
brain dysregulation by an altered peripheral immune
system and aberrant signaling at BBB.
Persons meeting clinical high-risk criteria have about a
20% risk of developing a psychotic disorder within two
years, and that is 100-fold higher than the 0.2% general
population risk6. Baseline factors differentiating clinical
high-risk subjects that convert to psychosis vs do not
convert may be of etiologic signiﬁcance. Previous psy-
chosis risk prediction studies compared levels of immune
signaling molecules, individually or in a linear combina-
tion3–5,7. Since responses of the peripheral immune sys-
tem are highly coordinated, investigation of the
correlation patterns of immune signaling molecules might
also be informative. In this analysis we sought networks of
highly correlated immune molecules in persons at clinical
high-risk who developed psychosis, compared to those
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who did not develop psychosis over the two-year follow-
up period. We also analyzed data from unaffected com-
parison subjects. In some respects, the correlation net-
works were strikingly different in converters. Some
distinguishing proteins were modulators of extracellular
matrix (ECM) components and BBB.
Schizophrenia pervasively impacts brain functions,
typically causing in adolescence or early adulthood dis-
ability that is chronic and relapsing. Improved clinical
outcomes are often associated identiﬁcation and treat-
ment of the disorder early in its course8, implying the
desirability of seeking reliable predictors based upon
readily accessible biomarkers. Moreover, early indicators
might be close to the ultimate causes of schizophrenia.
Thus, researchers (e.g., Domenici et al.9 and Dickerson
et al.10) have investigated in particular proteins and other
blood plasma analytes that distinguish unaffected com-
parison subjects from patients with schizophrenia or
subsets of such patients11,12. Included among the analytes
have been concentrations of circulating cytokines and
other immune system signaling molecules. These can be
altered in schizophrenia across all stages of the disorder
including the prodromal stage.
One key concept of this paper is information from
networks. As Fredrickson et al.13 stated, “…accumulation
of many individually noisy indicator variables can yield
highly stable estimates of the underlying factors they
share in common.” Thus, we sought networks of highly
correlated signals among each of three groups (converters,
nonconverters, and unaffected comparison subjects) from
our North American Prodrome Longitudinal Study
(NAPLS) project14. The emphasis was analysis of data
collected at the prodrome state (see Supplement Figure
S1). To place the present work in context, NAPLS is a
multi-site program that has accumulated, cleaned, stored,
analyzed, and reported many types of clinical and
laboratory assays, leading to proposals of various pre-
dictors and mechanisms for the development of
psychosis15.
Thus, the present emphasis differs from some earlier
works in that it is longitudinal and it pertains entirely to
networks. The three networks from the three groups are
formed by proteins that are highly correlated over subjects
in each group, far more highly correlated than could be
reasonably explained by chance. All of the reported cor-
relations are positive because there we observed no
negative correlations of the same, very high magnitude.
Many of the distinguishing analytes we found turned
out to be prominent in the immune system3 and its
interaction with trophic factors and ECM components.
Thus, the proper arena of this paper became neu-
roimmunology. Particularly in the last decade, many
important reports have developed this view of mental
illnesses (e.g., Khandaker et al.16).
A second key concept is the pleiotropic roles of proteins
customarily considered in the context of hemostasis vs
hemorrhage. Speciﬁcally, as Nave and Ehrenreich demon-
strated17, “It is becoming apparent that coagulation factors
do much more than simply act in the blood-coagulation
cascade.” For example, ﬁbrinogen associates with schizo-
phrenia18, Alzheimer disease19, and multiple sclerosis (MS)20.
A third key concept is that the peripheral immune
system impacts physiological and pathological brain
function21–23. We have hypothesized that peripheral
immune system dysregulation may contribute to devel-
opment of psychosis. Furthermore, the construction of
the above classiﬁer3 survived permutation testing very
well, implying that certain peripheral blood plasma pro-
teins and conversion of patients to schizophrenia are
associated. Finally, dysregulation of BBB permeability,
transendothelial cell migration, or remodeling of brain
ECM or vasculature—all impacted by the immune system
—could obviously be important in the events leading to
frank psychotic mood disorders including schizophrenia.
Materials and methods
Subjects
The aims and methods of North American Prodrome
Longitudinal Study (NAPLS2) were described in detail
previously24. Brieﬂy, NAPLS2 is an eight-site observa-
tional study of predictors and mechanisms of conversion
to psychosis. The NAPLS2 cohort includes 765 subjects at
clinical high-risk for psychosis, based on the Criteria of
Prodromal States, determined by the Structured Interview
for Prodromal Syndromes, and rated with the Scale of
Prodromal Symptoms25 (see Supplement). In addition, the
cohort includes 280 demographically similar unaffected
comparison subjects. Subjects were between ages 12 and
35 at baseline. Psychiatric diagnoses were determined by
the Structured Clinical Interview for DSM IV26. Clinical
assessments were performed every six months, and sub-
jects were followed for up to two years. The study was
approved by the Institutional Review Board at each site,
and each subject provided written informed consent or
assent, with a parent or guardian also consenting for
minor subjects. Demographics for subjects in the present
study are provided in Table 1.
Plasma analytes
During a baseline visit, blood samples were drawn using
Becton Dickenson P100 blood collection tubes containing
EDTA (as anticoagulant), proprietary protein stabilizers,
and a mechanical separator. Mean processing time to
−80 °C storage was 28 min (SD= 2min). Plasma samples
were subsequently sent on dry ice to Myriad RBM (Austin
TX), a laboratory that has maintained CLIA Accreditation
since 2006. Samples were analyzed with the Human
DiscoveryMAP v. 1.0 assays of 185 analytes associated
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with immune system function, hormonal responses, oxi-
dative stress, and metabolism. In total 141 analytes passed
preliminary quality control and were used in our analyses.
We standardized to z-scores the results for each analyte
using the average and SD values of the unaffected
comparison subjects. Quality control, normalization
methods, and tests with duplicated samples were per-
formed, as previously described3.
Data analyses
We used an unweighted co-expression network analysis
to identify highly correlated networks of analytes in each
of the three groups. Pearson correlations were calculated
using macros and built-in functions in Excel. Limited by
the smallest group size (converters, n= 32), we performed
random re-sampling with replacement 10,000 times by
drawing subgroups of 28 subjects from each of the three
groups. In other words, the 9870 pairs of analytes were
compared in 28-dimensional space 10,000 times to cal-
culate Pearson correlations. We compared those correla-
tion values to a common threshold and then recorded the
number of times a pair exceeded the threshold (ﬂowcharts
in Supplement Figure S2). The correlation threshold
selected was 0.7662; if two 28-dimensional vectors were
populated by a Gaussian distribution, then the probability
of their correlation exceeding this value would be 1E-6.
Thus, with 9870 pairs of analytes, we expect only 1 such
value among all pairs about once in 100 trials.
Considering all 107 subjects and all 9870 pairs of ana-
lytes at once, distribution analysis using EasyFit
(MathWave, Dnepropetrovsk, Ukraine) revealed that no
normal distribution ﬁt the observations but the Johnson
SU distribution
27 did. Technically, normal distributions
failed to ﬁt the observed distribution of correlations in
both Kolmogorov–Smirnov and Anderson–Darling tests
for even α= 0.01; by contrast, the Johnson SU distribution
achieves α= 0.2 in both tests. The Johnson SU distribu-
tion accommodates a one-sided tail of very strong, posi-
tive correlations not balanced by even one negative
correlation of equal magnitude. Therefore, we focused on
only the very strong, positive correlations (Fig. 1).
We validated our approach by ﬁrst randomly permuting
all 107 subjects, then analyzing 28-subject subsets of the
pseudo-groups exactly as if they were from the true data.
Neither the design nor the implementation of the algo-
rithm conferred any obvious, consistent distinction to
edge counts of graphs of very strong correlations in the
three pseudo-groups. This result indicates that both the
design and implementation of the program correctly
achieved unbiased identiﬁcation of correlation networks.
Measures of network complexity include those of
Bonchev and Buck28 (see their formulas 19a,b) in which
the normalized edge complexity is the number of
(undirected) edges e divided by the maximum possible
number of edges using the same number of vertices v,
namely, v*(v-1)/2.
Protein network analyses were conducted using Inge-
nuity Pathway Analysis (IPA) (QIAGEN N.V., Venlo, The
Netherlands).
Table 1 Demographic and clinical characteristics of study
subjects taken at baseline of longitudinal study
Unaffected
comparison
(UC) N= 35
Clinical high-risk,
nonconverters
(CHR-NC) N= 40
Clinical high-
risk,
Converters
(CHR-C) N=
32
Age, average (SD) 20 (4.5) 19.5 (4.6) 19.2 (3.7)
Ancestry
%Caucasian 60%, 65% 55%
%African 31% 17.5% 21%
%Asian 9% 17.5% 24%
Sex, % female 34% 37.5% 30.3%
SES, average (SD) 4.8 (1.8) 4.5 (2.3) 4.5 (1.8)
Time blood draw,
average (SD)
12.:12 pm
(1.85 h)
12:39 pm (2.0 h) 11:59 am
(1.79 h)
Prescription medication
Antipsychotica 0% 25% 13%
Antidepressantb 1% 30% 25%
Stimulant 0% 8% 6%
Mood stabilizer 0% 5% 3%
Benzodiazepinec 0% 5% 13%
NSAID 0% 0% 0%
Antibiotic 0% 0% 0%
Substance Use
Tobacco used 9% 30% 44%
Alcohol use 46% 48% 38%
Marijuana usee 9% 25% 31%
Current co-morbid DSM IV Diagnosis
Depressionf 0% 45% 50%
Anxiety
Disordersg,*
3% 60% 56%
aCHR-C vs UC FET p-value= 0.047, CHR-NC vs UC Fisher Exact Test (FET) p-value
= 0.001
bCHR-C vs UC FET p-value= 0.011, CHR-NC vs UC FET p-value= 0.002
cCHR-C vs UC FET p-value= 0.047
dCHR-C vs UC FET p-value= 0.001, CHR-NC vs UC FET p-value= 0.02
eCHR-C vs UC FET p-value= 0.020, CHR-NC vs UC FET p-value= 0.056
fCHR-C vs UC FET p-value < 0.0001, CHR-NC vs UC FET p-value < 0.0001
gCHR-C vs UC FET p-value < 0.0001, CHR-NC vs UC FET p-value < 0.0001
*Depression disorders include Major Depression, Depressive Disorder Not
Otherwise Speciﬁed, and Dysthymic Disorder. Anxiety Disorders include
Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, Panic Disorder,
Agoraphobia, Social Phobia, Speciﬁc Phobia, Generalized Anxiety Disorder
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Results
Protein correlation networks distinguish the three groups
There was a striking loss of network complexity going
from unaffected to nonconverters and thence to converter
subjects. Analyte pairs with Pearson correlations exceed-
ing an a priori threshold in at least 5000 of 10,000 random
draws of 28 subjects from each group are shown for
unaffected subjects (Fig. 2), nonconverters (Fig. 3), and
converters (Fig. 4).
For unaffected, nonconverter, and converter groups we
calculated a simple metric of graph complexity, namely
the ratio of numbers of edges to vertices; respective values
were 1.48, 1.30, and 0.89 edges per vertex. Normalized
edge complexities were 0.134, 0.119, and 0.062. Moreover,
it is visually apparent that the three graphs are quite dif-
ferent in terms of edge densities. Additional graphs and
experiments with alternative choices of thresholds led to
the same trend and are in the Supplement. This trend
toward simplicity going from unaffected to nonconverter
to converter for plasma proteins parallels the same for
leukocytic microRNAs reported earlier29.
Notably, in unaffected subjects there was a network
involving the proteins SERPINE1 (plasminogen activator
inhibitor-1), MMP7, MMP9 (activated), MMP9t (total),
and MMP10 (matrix metalloproteinases). While SER-
PINE1 is anti-remodeling, the others are pro-remodeling,
and a balance (correlation of some pairs) might be
expected in hemostasis vs hemorrhage. In contrast, non-
converters and converters lacked these strong SERPINE1
correlations. Furthermore, while the important inhibitor
of remodeling TIMP1 (tissue inhibitor of metalloprotei-
nases) was absent (at the chosen threshold for inclusion)
from strong correlations in unaffected and nonconverter
graphs, it generally exceeded the threshold correlation
value with SERPINE1 in converter subjects. In detail, the
SERPINE1 vs TIMP1 correlations exceeded the threshold
in the three sets of 10,000 random draws of 28 subjects in
totals of <10, <10, and >8300 times, respectively. As sets,
Fig. 2 Unaffected comparison subject data yielded a graph of strongly correlated analytes with 23 analytes (vertices) and 34 robust
correlations (edges). Blood plasma proteins are labeled by their gene common symbols. The correlations in orange appear in all three graphs. We
note eight analytes that include SERPINE1, and in particular SERPINE1 correlations include the matrix metalloproteinases MMP7, MMP9, and MMP10.
MMP9t denotes an assay for both pro-MMP9 and mature MMP9
Fig. 1 A histogram with 20 bins of 9870 correlation values
among 141 analytes over all 107 subjects. The shown distribution
is a Johnson SU ﬁt with four parameters: gamma=−1.2967, delta=
2.2624, lambda= 0.26593, xi=−0.12371. The present study is
distinguished from many others by focusing on the tail of very strong,
positive correlations (blue box) that are not balanced by any negative
correlations of the same magnitude
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the actual SERPINE1 and TIMP1 correlation values over
10,000 draws for converter subjects (mean correlation=
0.79, SD= 0.03) tended to be signiﬁcantly greater (p-
value < 1E-100) than the values in nonconverters (mean
= 0.55, SD= 0.06) and unaffected subjects (mean= 0.50,
SD= 0.09). The dramatic distinction of SERPINE1 and
TIMP1 correlations in converters is further illustrated in
the Supplement (Figure S10).
What could explain the extremely high correlations of
SERPINE1 and TIMP1 in converters only? We note that
another protein, CTGF (connective tissue growth factor),
is known to promote mutual expression of SERPINE1 and
TIMP1 and so might be part of the explanation (see
Discussion).
From a previous study by Domenici el al.9 we evaluated
SERPINE1 vs TIMP1 correlations. The subjects con-
tributing to that study were schizophrenia patients and
controls. We calculated correlations for 10,000 random
subsets of 200 subjects drawn randomly from 267 control
subjects and 229 schizophrenia patients. The results
(Supplement Figure S11) indicated patients had far
stronger SERPINE1 vs TIMP1 correlations than controls.
Fig. 4 Converter data yielded a graph of strongly correlated analytes with 27 analytes and 24 robust correlations. Four SERPINE1
correlations are present, suggesting changes in requlation of the SERPINE1 gene compared to unaffected and nonconverter assays. Remarkable is the
gained correlation of SERPINE1 and TIMP1 because both proteins inhibit anticogulation and vascular remodeling in some contexts and both
generally promote anti-inﬂammation. Furthermore, TIMP1 is completely absent in unaffected and nonconverter graphs. Also, the strong SERPINE1
correlations with matrix metalloproteinases (MMPs) in the unaffected graph are absent in this converter graph
Fig. 3 Nonconverter data yielded a graph of strongly correlated analytes with 23 analytes and 30 robust correlations. SERPINE1 correlations
are completely absent, suggesting a loss of requlation of expression of the gene
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Subnetworks common among all three groups
Several pairs of analytes were highly correlated in all
three groups (highlighted in orange in Figs. 2, 3, and 4).
Among them was the complete graph formed by inter-
leukins 3, 5, 7, and 13. We examined the correlation
pattern of these interleukins in the Domenici data9 for 267
unaffected subjects. As shown in the Supplement Figure
S9, the four interleukins were highly correlated in that
cohort as well.
Discussion
Immune correlation networks and psychosis risk
Psychosis conversion in high-risk subjects was char-
acterized by marked simpliﬁcations of networks of cor-
related proteins that regulate tissue remodeling; this
might be consistent with the hypothesis of BBB dysre-
gulation in schizophrenia30. Notable were graph changes
involving SERPINE1. The serine protease inhibitor SER-
PINE1 is the major inhibitor of the plasminogen activator
PLAT; PLAT activates plasminogen to plasmin (the ﬁnal
substrate of the ﬁbrinolytic system) which in turn
degrades ﬁbrin. Thus, a focus infra is SERPINE1 and
related proteins31.
Relevant to the present study, schizophrenia patients are
subject to increased risk of cardiovascular disease,
reduced risk of certain types of cancer, and possibly some
aspects of accelerated aging; all these general observations
have in turn been associated with SERPINE1 or related
proteins32–36.
More particularly, connection of schizophrenia with
proteins important in coagulation homeostasis has been
ampliﬁed by recent studies of Hoirisch-Clapauch, Nardi,
and their colleagues37, starting with anecdotal descrip-
tions of possible beneﬁts to ﬁve schizophrenia patients of
treatment with warfarin (which would seemingly counter
the effects of increased SERPINE1 and decreased PLAT
activity). They proposed that normalization of levels of
PLAT in the psychotic brain might enable long-term
remission of psychotic symptoms.
PLAT is secreted by many cell types including blood
vessel endothelial cells that are known to express diverse
genes differentially even among regions of the same
artery38–40. In neurons PLAT occurs in dendrites and
synapses; it is stored in pre-synaptic vesicles that cross the
synaptic cleft after depolarization, subject to regulation by
astrocytes41,42.
Aside from hemostasis, PLAT has related roles in
smooth muscle signaling in blood vessel tunica31,43, sev-
eral types of ECM signaling44, and BBB permeability in
the context of cerebral ischemia45. Given the large num-
bers of schizophrenia patients who are comorbid for
cardiovascular diseases, who require treatment with
warfarin or functionally related pharmaceuticals, and who
are not in remission, the intersection of hemostasis and
psychosis cannot be simple. However, Hoirisch-Clapauch
et al.34,46. provided additional reasoning and evidence of a
connection, ﬁnding lower PLAT levels among 70 schizo-
phrenia patients compared with 98 age-matched controls.
Since the principal regulator of PLAT levels is SERPINE1,
Hoirisch-Clapauch and Nardi46 postulated that inﬂam-
matory conditions could increase the risk of schizo-
phrenia through mechanisms involving SERPINE1 levels.
PLAT is highly pleiotropic as, therefore, might be some
of its regulators. Two of many reported PLAT substrates
directly relevant to psychiatry have functions in epidermal
growth factor receptor (EGFR)-mediated neuroprotec-
tion47,48 and the dynamics of the glutamate receptor and
ion channel protein NMDAR (antagonized by phencycli-
dine in a model of schizophrenia)49,50. Furthermore,
PLAT is expressed in brain endothelial cells, neurons, and
microglia. It is strongly and negatively correlated with
mRNA for OCLN (occludin)51, a protein important in the
stability and permeability of tight junctions. Reactive
oxygen species can cause rapid release of PLAT in
monocyte and endothelia cocultures52. In a related effect
(noting the above correlations in unaffected subjects),
MMP9 promotes monocyte migration through brain
parenchymal basement membrane52.
Consistent with our ﬁndings, there is also an emerging
literature implicating the plasminogen pathway in schi-
zophrenia. This literature points towards down-regulation
of PLAT, up-regulation of factors including SERPINE1
that inhibit PLAT activation34,37,46,53, and consequences
of elevated ﬁbrinogen (ﬁbrin) including incorrect differ-
entiation of progenitors of oligodendrocytes into astro-
cytes in MS20. This misguided differentiation might relate
to reported low levels of oligodendrocytes in layer ﬁve of
prefrontal cortex in schizophrenia54.
For data from the same subjects presently studied we
previously reported that proteins involved in the plasmi-
nogen pathway, including MMP7 and Factor 7, predicted
psychosis conversion3. In our previous publication we did
not ﬁnd that expression levels of SERPINE1 or TIMP1
were substantially increased going from nonconverters to
converters. By contrast, the current study suggests that
the extreme changes in correlation networks of SER-
PINE1 and related proteins, especially TIMP1, may
indeed be informative.
Most notable is an interpretation of CTGF in idiopathic
pulmonary ﬁbrosis55,56 and other diseases57–59 that might
explain the remarkable correlation of SERPINE1 and
TIMP1 levels in converters. Unfortunately, in our blood
plasma assays CTGF was not detected in 50–70% of the
subjects in all three of the groups, precluding its corre-
lation analysis. However, regarding CTGF as a known
driver of SERPINE1 and TIMP1 levels, we note that local
upregulation of CTGF by a type of alveolar cell, resulting
in proliferation of local ﬁbroblasts, has been proposed as a
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surrogate biomarker of idiopathic pulmonary ﬁbrosis
(IPF);55 CTGF is therefore the target of ongoing IPF
clinical trials of the fully human monoclonal antibody
Pamrevlumab by FibroGen (San Francisco CA) (trial
NCT01890265 at ClinicalTrials.gov).
The serine protease inhibitor SERPINE1 is a “suicide
protein” in the serpin superfamily and is the major inhi-
bitor of the plasminogen activator PLAT and related
protein PLAU (plasminogen activator urokinase). Thus,
SERPINE1 is a crucial down regulator of ﬁbrinolysis and
ECM degradation31. In wound healing, SERPINE1 con-
tributes to regulation of cell proliferation and tissue
remodeling43, as well as other aspects of cell signaling and
migration44,45.
Studies of samples from clinical high-risk psychiatric
patients in the literature34 and in our data (Supplement
Figure S10) can exhibit somewhat elevated levels of
SERPINE1. Interestingly, de Fouw et al.60 reported that
the glycoprotein Protein S (PROS1) accelerated neu-
tralization of SERPINE1, thereby increasing PLAT activ-
ity; this ﬁnding suggests possibilities for indirect control
of PLAT levels and function. In its free form, PROS1 is a
cofactor of protein C (PROC) in the anticoagulation
pathway. PROS1 and PROC are vitamin K-dependent
plasma proteins61, included among the cofactors in the
inactivation of the prothrombinase complex. PROS1 also
exists in a complex with complement C4B-binding pro-
tein62. Complement inhibitor C4B-binding protein
enhances plasminogen activation63. Isotypes of the C4
protein have been implicated in schizophrenia gene
association studies64.
SERPINE1 levels are up-regulated by inﬂammatory
cytokines including IL6, TNF, and TGFB1, as reviewed by
Brown et al.65. These researchers postulated that inﬂam-
matory conditions increased the risk of schizophrenia
through a combination of mechanisms involving
increased SERPINE1 levels or decreased free PROS1
levels.
PLAT was not measured in our assays, but more should
be said about some of its extensive functions66,67. PLAT
degrades ECM and in particular cleaves the large glyco-
protein RELN, all contributing to cell migration and tissue
remodeling, particularly revascularization. PLAT affects
neural, endothelial, and glial cells, driving multiple,
sometimes opposing effects by activating or otherwise
regulating diverse transcription factors and receptors.
Regarding the neurotrophin BDNF (brain-derived neu-
rotrophic factor), PLAT promotes the cleavage of neu-
ronal proBDNF to mature BDNF, a function essential for
late-phase long-term potentiation68. Pro- and mature
BDNF have important and opposing effects on synaptic
plasticity, regulation of neurogenesis, and neuronal sur-
vival69. Only the mature BDNF was assayed by us; it is
prominent in Figs. 2–4.
MMP9 is also an important factor in ECM maintenance
and remodeling, assayed herein both as mature MMP9
and as the total of proMMP9 and mature MMP9 (labeled
MMP9t in our graphs). It regulates glutamate receptors,
modulates physiological and morphological synaptic
plasticity, and is regulated by glutamate at excitatory
synapses70. MMP9 and other extracellular proteases such
as plasmin convert proBDNF to mature BDNF71. PLAT,
PLAU, plasmin, and MMP9 all have roles in BBB dis-
ruption after stroke72. MMP9 itself is activated in pre-
sence of oxidative stress and in turn promotes the
receptor for advanced glycation end-product (RAGE) (to
be described in a forthcoming paper by D. Dwir et al.),
said to induce a self-reinforcing cycle of inﬂammatory
responses and further oxidative stress73,74. In addition,
MMP9 is involved in the degradation of the perineuronal
net, a type of ECM that wraps fast-spiking parvalbumin
interneurons; the perineuronal net is known to be affected
in the medial prefrontal brain of schizophrenia
patients75,76. In mice, intravenously administered PLAT
was detected within the brain parenchyma and cere-
brospinal ﬂuid, having crossed the BBB by transcytosis77.
In summary, for converter subjects SERPINE1 was no
longer correlated with antithetical MMPs, but instead
became highly correlated with the synthetical TIMP1.
This observation and the above integration of these pro-
teins and CTGF in multiple disorders suggest the poten-
tial importance of CTGF inhibition. Several inhibitors of
CTGF have been proposed and studied; for example,
insulin and an siRNA have been studied in the context of
inhibition of vascular remodeling in diabetic retino-
pathy78. However, certain advantages attend a mono-
clonal antibody for CTGF inhibition.
Interleukin networks common in all subjects
We found that IL3, IL5, IL7, and IL13 form a highly
correlated module in all groups, and replicated this ﬁnding
in an external test set of unaffected subjects (Figure S8),
suggesting co-regulation and closely related functions of
these cytokines. Three genes, IL3, IL5, and IL13 (and also
IL4), exist as a cytokine gene cluster on chromosome arm
5q. Unfortunately, IL4 detection was weak (below LLOQ)
or missing in more than half our samples, precluding
correlation analysis with the rest of that cluster. But IL4
and IL7 are among the six “γ-chain utilizing” interleukins,
while IL3, IL4, IL5, and IL13 are the four “IL4-like”
interleukins; both sets of proteins are considered tightly
packed α-helices in a four-helix bundle motif of short core
helices79. There are about 45 human interleukins, so the
members of the identiﬁed correlation cluster are more
similar than would be expected by chance.
The top shared pathway for IL3, IL5, IL7, and IL13 from
application of IPA was “hematopoiesis from multipotent
stem cells” (p= 1.6E-9). IL3 promotes hematopoietic
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stem cell proliferation, and IL7 regulates development of
the common lymphoid progenitor cells and development
of B-cell, T-cell, and NK-cell lineages. In detail, IL3 reg-
ulates development of the common myeloid progenitor,
and IL5 regulates development of neutrophils and eosi-
nophils80. Less is known regarding IL13, but its receptor,
IL12A1, is selectively expressed on CD62L+ cells (com-
mon lymphoid progenitors), again suggesting a role in
regulation of lymphoid cell differentiation81. Normally,
the circulating proportions of neutrophils, lymphocytes,
monocytes, and eosinophils are relatively constant, so
possibly IL3, IL5, IL7, and IL13 in our graphs contribute
to maintenance of homeostatic proportions of those cell
types.
Limitations
Foremost among limitations, the sample sizes of the
three groups in our study were all small. We plan to add
data from more subjects in the near future (NAPLS3). In
addition, the Luminex platform is less reproducible for
certain proteins than other platforms, including Meso-
Scale, ELISA, and microﬂuidic ELISA. We plan to employ
microﬂuidic ELISA in pending analyses. Another limita-
tion is the two-year limit for the deﬁnition of conversion.
Although the rate of psychosis conversion is much lower
after two years, we anticipate that up to 10% of our
nonconverters will eventually convert to psychosis,
implying some uncertainty in all our statements about
nonconverters vs converters. However, by considering
only networks constructed from extremely high correla-
tions and thousands of random subsets of the groups, we
consider it unlikely that the ﬁndings could be explained
entirely by chance alignments. Lastly, many proteins
functionally related to those in our assays were not con-
sidered due to costs. Therefore, important signals might
be missing from our analyses. Despite all the seemingly
plausible relationships described supra, our ﬁndings need
conﬁrmation and expansion in other cohorts. Further
work of multiple types, e.g., as that being undertaken by
Sorokin82, is required to directly link peripheral immune
dysregulation to the etiology of schizophrenia.
Translation to the clinic
The present work suggests that additional longitudinal
studies of clinical high-risk patients with logically
expanded assays of agents of immune responses could
lead to parsimonious lists of proteins implicated in con-
version to schizophrenia. Ratios of distinguishing proteins
for a new patient could be compared with historical ratios
to predict membership among nonconverters or
converters.
Furthermore, the above potential connection of SER-
PINE1 and TIMP1 expression with CTGF regulation
might lead to investigation of Pamrevlumab (http://www.
ﬁbrogen.com/pamrevlumab-trials/) or related agents of
CTGF inhibition. The potential medical value of inhibi-
tion of CTGF in various diseases has long been recog-
nized. The recent appearance of Pamrevlumab as a
potential treatment for IPF and its repurposing suggested
herein for prevention of conversion to psychosis might be
especially important. Repurposing is a drug development
strategy with huge savings of time and expense.
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